You are here: Industry Insights > T-cell

News List

Another Giant Entering, the TIGIT Antibody Market is Highly Competitive PharmaSources/Dopine
July 09, 2021
GlaxoSmithKline (GSK) and iteos Therapeutics have announced a collaboration to jointly develop and commercialize EOS-448. EOS-448 is an anti-TIGIT monoclonal antibody, which is in the phase I development.
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares firstwordpharma
June 18, 2021
PDS Biotechnology Corporation today announced the closing of its previously announced underwritten public offering of 6,088,235 shares of common stock at a public offering price of $8.50 per share.
Phase I clinical trial outcome shows Covaxin generates antibody, T-cell memory response expresspharma
December 24, 2020
Bharat Biotech’s COVID-19 vaccine Covaxin has shown positive long term antibody and T cell memory response in Phase I clinical trial.
Using Th17 cells researchers make adoptive T-cell transfer therapy viable europeanpharmaceuticalreview
November 12, 2020
Adoptive T-cell transfer therapy has had limited use due to the time involved in CD8+ T cell expansion, using a different type of T cell researchers were able to shorten this timeline, making the therapy more accessible.
Astellas, CytomX form T-cell engaging cancer antibodies partnership pharmatimes
March 27, 2020
Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
CASI Acquires Anti-CD19 T-cell Therapy from Juventas contractpharma
June 18, 2019
In lieu of the upfront payment, CASI Pharmaceuticals (Wuxi) Co., will invest approximately $11.6 million in Juventas .
Adaptimmune, Alpine Immune Sciences Enter Next-Gen SPEAR T-Cell Pact contractpharma
May 16, 2019
Adaptimmune to license Alpine’s Immunomodulatory Protein technology for use with SPEAR T-cells to enhance anti-tumor responses.
Takeda forms new alliances to boosts immuno-oncology portfolio pharmaceutical-technology
January 07, 2019
Takeda Pharmaceutical has formed new research alliances to bolster the discovery of next-generation immunotherapies, including cell therapy techniques, for the treatment of cancer......
Harpoon files $86M IPO to help fund its T-cell engager platform fiercebiotech
January 04, 2019
Fresh off raising $70 million through a series C round just over a month ago, Harpoon Therapeutics announced it will go public with an $86.25 million IPO to further support its portfolio of early-stage T-cell engagers aimed at solid tumors.....
Technology Advancements to Conquer the Precision Medicine Market prnasia
January 18, 2018
Targeted and personalized therapeutics are likely to alter the existing precision medicine landscape.

Previous page 1 2 Next page